Aarti Pharmalabs Limited · NSE:AARTIPHARM
Aarti Pharmalabs — Q1 FY2024 Earnings Presentation
26 slides from Aarti Pharmalabs's earnings presentation
Slide 1: Aarti Pharmalabs Limited Q1 FY24 Results Presentation
Aarti Pharmalabs Limited Q1 FY 24 Results Presentation
Slide 2: Disclaimer
Disclaimer AARTI PHARMALABS LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not u
Slide 3: Index
Index 1 Company Overview 2 Financial Performance 3 APL Growth Strategies
Slide 4: Company Overview
Company Overview ………………………………………………..
Slide 5: Aarti Pharmalabs at a Glance
Aarti Pharmalabs at a Glance Overview FY 23-24 Q1 - Consolidated Revenue Breakup (Rs Cr) ▪ Established by first generation technocrats in 1984 ▪ Specialized key business verticals ■ API & Intermediates, ■ CDMO & CMO Services ■ Xanthine derivatives & allied ▪ Strong R&D capabilities with IPRs for cust
Slide 6: Journey
Journey Expanded block •Unit 5 commissioned for CSD, Vapi and for Caffeine Production Oncology block API, Tarapur. with a capacity of 100 at Unit 4 Commissioning of first 1st Clearance of the Oncology block at MT per month audited by Acquired Land at Incorporated API manufacturing Unit USFDA & EUGMP
Slide 7: Manufacturing Facilities
Manufacturing Facilities Unit - II Custom synthesis Manufacturing Location division (CSD) Units Location: Vapi Dombivali Unit - I (API & Intermediates) R&D Centers Unit - II (API Intermediates & Vapi Location: Vapi, Custom Synthesis Unit) Unit – III (Xanthine Unit) Gujarat Dombivali Greenfield Proje
Slide 8: Key Business Verticals
Key Business Verticals APIs and Intermediates CDMO / CMO Services Xanthine derivatives & Allied (Caffeine and others) ❏ US FDA approved manufacturing facility ❏ CRAMs activity focused on API & intermediates ❏ Largest Indian Manufacturer for ❏ Exports to lucrative regulated markets - US, EU and Japan
Slide 9: Key Business Verticals
Key Business Verticals AARTI PHARMALABS Business wise sales break up Q1 FY 24 CMO CDMO 6.3% API & Intermidates Xanthine& Others
Slide 10: Strong Presence in API & Intermediates
Strong Presence in API & Intermediates 50 10 40 20 ~100 APIs have been New APIs are under US DMF approvals CEP approvals Generic Intermediates commercialized by APL development at APL’s obtained across available for sale in are available at R&D, since it entered the dedicated R&D facility multiple t
Slide 11: CDMO / CMO
CDMO / CMO ❏ Sustainable supply for APIs/NCEs/Intermediates in commercial scale ❏ Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS) ❏ EHS and Quality are the highest priority. Facilities were audited as per PSCI principles ❏ High potent molecules (Oncology/Cytotoxic) development
Slide 12: Manufacturing Capabilities & Strengths
Manufacturing Capabilities & Strengths Impeccable Strong expertise in regulatory track Hydrogenation 20+ years of development of HPAPI (Cytotoxic/ record (>15 years) Backward facilities from lab Cryogenic reactors experience in robust & Oncology) and High temperature and facilities integration of ra
Slide 13: Xanthine Derivatives
Xanthine Derivatives • Xanthine derivatives are synthetic End Use Certifications compounds that resemble natural occurring xanthines such as caffeine etc., • Commonly used as mild stimulants & Cola Drinks Energy Drinks bronchodilators, notably in the treatment of asthma or influenza symptoms • 2 dedi
Slide 14: R&D Strengths & Capabilities
R&D Strengths & Capabilities 3 70+ 7 13 52 State-of-the-art R&D centres at Maharashtra & Scientists PHDs. Patents Granted Process patents filed Gujarat 150+ 50+ Process for more than 150 Intermediates developed More than 75 API and manufactured on kilo commercialized lab scale 160 39 crs R&D Spend in
Slide 15: Strong Focus on R&D & Process Innovation
Strong Focus on R&D & Process Innovation Innovation at various reactions ● Carbohydrate Chemistry ● Chiral Chemistry ○ Asymmetric Synthesis ○ Bio Catalysts ○ Chiral Epoxides ○ Kinetic Resolution ● Coupling Reactions Chemistry ○ C-C Coupling ○ C-N Coupling ● Isomerization Reactions ● Triphosgene Reac
Slide 16: ESG at APL
ESG at APL Environment - Highlights Social - Highlights Governance - Highlights ● ISO 14001 : 2015 certification ● Hazard Identification and Risk Assessment • Robust Compliance Monitoring (HIRA), Hazardous Area Classification Framework - implemented PWC’s ● All plants are Zero Liquid Discharge (HAC) an
Slide 17: Financial Performance
Financial Performance ………………………………………………..
Slide 18: Q1 FY24: Highlights (Consolidated)
Q1 FY24 : Highlights (Consolidated) Revenue from EBITDA Highlights of Q4 FY 24 operations INR 458 crs INR 85 crs -5.5% QoQ 6 % QoQ ❏ Revenues declined on account of a drop in prices mainly of Xanthine Products. The decrease in Selling price was to a significant extent was compensated by increase in V
Slide 19: Q1 FY24 Highlights (Consolidated)
Q1 FY24 Highlights (Consolidated) Revenues EBITDA Profit Before Tax Profit After Tax 19
Slide 20: Key Performance Indicators Q1 FY24 – Consolidated Profit & Loss
Key Performance Indicators Q1 FY24 – Consolidated Profit & Loss Particulars (Rs. Crore) Q1 FY24 Q4 FY23 Q-o-Q (%) Q1 FY23 Y-o-Y (%) Gross Income from Operations 458 485 -5.50% 457 0.21% Exports 169 204 -17.32% 193 -12.58% % of Total Income 36.7% 42.0% 42.1% EBITDA 85 81 5.73% 85 0.76% EBITDA Margin
Slide 21: Key Performance Indicators Q1 FY24 – Standalone Profit & Loss
Key Performance Indicators Q1 FY24 – Standalone Profit & Loss Particulars (Rs. Crore) Q1 FY24 Q4 FY23 Q-o-Q (%) Q1 FY23 Y-o-Y (%) Gross Income 363 374 -3.01% 373 -2.72% Exports 143 162 -11.73% 179 -20.11% Exports % 39% 43% 48% EBITDA 82 77 6.26% 79 3.67% EBITDA (%) 22.48% 20.52% 21.09% EBIT 66 63 5.
Slide 22: Q1 FY24 other highlights
Q1 FY 24 other highlights ➢ The Company continues to focus on selling APIs and Intermediate in the Regulated markets. During the last financial year 22-23, the Company commissioned an additional Block in its API manufacturing plant. The validation batch samples for a few key products are awaiting cus
Slide 23: Growth Strategies
Growth Strategies ………………………………………………..
Slide 24: Our Growth Strategy
Our Growth Strategy Increase in capacities of existing products & Adding new 40+ Value added product each year. Atali Project ● ~ 80 acres of land in Gujarat (between Dahej & Bharuch) Growth Develop and explore more Initiatives under ● Adding 400+KL reactor volume in Phase1 opportunities for innovat
Slide 25: Outlook
Outlook ◆ Rampup of new expended blocks at Unit IV, Tarapur & Xanthine Derivatives FY24 ◆ Expected EBIDTA Growth to be about 10-15% ◆ Commissioning of Blocks at Atali in phased manner from FY25. FY25 and ◆ Rampup @ Atali project will bring in operating leverages in FY26 and beyond beyond ◆ Expecting
Slide 26: Thank You
THANK YOU Aarti Pharmalabs Limited #204, Udyog Kshetra, 2nd Floor, Mulund Goregaon Link Road, Mulund West, Mumbai - 400080, Maharashtra, India. Email: investorrelations@aartipharmalabs.com Contact: +91 22 67976666